Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Go back to Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders| (NYSE: DTC) | Delayed: 19.55 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.55 | 52 Week High | $ | |||
| Open | $19.55 | 52 Week Low | $ | |||
| Day High | $19.55 | P/E | N/A | |||
| Day Low | $19.55 | EPS | $ | |||
| Volume | 208,325 | |||||
| (AMEX: DTCFF) | Delayed: 0.29 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.29 | 52 Week High | $ | |||
| Open | $0.29 | 52 Week Low | $ | |||
| Day High | $0.29 | P/E | N/A | |||
| Day Low | $0.29 | EPS | $ | |||
| Volume | 500 | |||||



